Please Wait
Applying Filters...
menu
    • menu
    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Hubei Gedian Humanwell Pharmaceutical Abiraterone Acetate

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Abiraterone Acetate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,851Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 154229-18-2, Zytiga, Cb7630, Cb-7630, Yonsa, Cb 7630
    Molecular Formula
    C26H33NO2
    Molecular Weight
    391.5  g/mol
    InChI Key
    UVIQSJCZCSLXRZ-UBUQANBQSA-N
    FDA UNII
    EM5OCB9YJ6
    An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
    2.1.2 InChI
    InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1
    2.1.3 InChI Key
    UVIQSJCZCSLXRZ-UBUQANBQSA-N
    2.1.4 Canonical SMILES
    CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C
    2.1.5 Isomeric SMILES
    CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC=C4C5=CN=CC=C5)C)C
    2.2 Other Identifiers
    2.2.1 UNII
    EM5OCB9YJ6
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 17-(3-pyridyl)-5,16-androstadien-3beta-acetate

    2. Cb 7630

    3. Cb-7630

    4. Cb7630

    5. Zytiga

    2.3.2 Depositor-Supplied Synonyms

    1. 154229-18-2

    2. Zytiga

    3. Cb7630

    4. Cb-7630

    5. Yonsa

    6. Cb 7630

    7. Abiraterone Acetate [usan]

    8. 17-(3-pyridyl)-5,16-androstadien-3beta-acetate

    9. Em5ocb9yj6

    10. [(3s,8r,9s,10r,13s,14s)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] Acetate

    11. Nsc-748121

    12. Nsc-749227

    13. Chebi:68639

    14. (3s,8r,9s,10r,13s,14s)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl Acetate

    15. 17-(pyridin-3-yl)androsta-5,16-dien-3beta-yl Acetate

    16. (3beta)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl Acetate

    17. Abiraterone Acotate

    18. 17-(3-pyridyl)androsta-5, Acetate

    19. Androsta-5, 17-(3-pyridinyl)-, 3-acetate,

    20. Unii-em5ocb9yj6

    21. Abiraterone-acetate

    22. Ncgc00186462-01

    23. 3s,9s,10r,13s,14s)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-ol, 3-acetate

    24. Abiraterone Acetate

    25. Mfcd00934213

    26. Zytiga (tn)

    27. Abiraterone (acetate)

    28. Jnj-212082

    29. Abiraterone Acetate- Bio-x

    30. Dsstox_cid_28969

    31. Dsstox_rid_83234

    32. Dsstox_gsid_49043

    33. Schembl93715

    34. Mls006010090

    35. Chembl271227

    36. Gtpl9288

    37. Abiraterone Acetate (jan/usp)

    38. 3beta-17-(3-pyridyl)androsta-5,16-dien-3-ol Acetate

    39. Abiraterone (as Acetate)

    40. Abiraterone Acetate [mi]

    41. Dtxsid3049043

    42. Abiraterone Acetate [jan]

    43. Ex-a107

    44. Abiraterone Acetate [vandf]

    45. Abiraterone Acetate [mart.]

    46. Bcp02949

    47. Zinc3809191

    48. Tox21_113589

    49. Abiraterone Acetate [usp-rs]

    50. Abiraterone Acetate [who-dd]

    51. Bdbm50407398

    52. Nsc748121

    53. Nsc749227

    54. S2246

    55. Abiraterone Acetate, >=98% (hplc)

    56. Akos015896502

    57. Cs-0544

    58. Ds-2007

    59. Jnj 212082

    60. Nsc 748121

    61. Nsc 749227

    62. Jnj-2012082

    63. Abiraterone Acetate [orange Book]

    64. Ncgc00379022-06

    65. Ac-25760

    66. Ba164133

    67. Hy-75054

    68. Smr004701235

    69. Abiraterone Acetate [usp Monograph]

    70. Cas-154229-18-2

    71. D09701

    72. 3b-acetoxy-17-(3-pyridyl)androsta-5,16-diene

    73. A809510

    74. 3beta-acetoxy-17-(3-pyridyl)androsta-5,16-diene

    75. W-201385

    76. Brd-k24048528-001-02-5

    77. Q27888393

    78. (3s)-3-acetoxy-17-(pyridin-3-yl)androsta-5,16-diene

    79. (3?)-17-(3-pyridinyl)androsta-5,16-dien-3-yl Acetate

    80. (3beta)-17-(3-pyridinyl)androsta-5,16-dien-3-ol Acetate

    81. 17-(pyridin-3-yl)androsta-5,16-dien-3.beta.-yl Acetate

    82. Abiraterone Acetate, United States Pharmacopeia (usp) Reference Standard

    83. Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, Acetate (ester), (3beta)-

    84. Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, Acetate (ester), (3.beta.)-

    85. (1s,2r,5s,10r,11s,15s)-2,15-dimethyl-14-(pyridin-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-7,13-dien-5-yl Acetate

    86. [(3s,8r,9s,10r,13s,14s)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] Ethanoate

    87. Acetic Acid [(3s,8r,9s,10r,13s,14s)-10,13-dimethyl-17-(3-pyridinyl)-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] Ester

    2.4 Create Date
    2006-10-25
    3 Chemical and Physical Properties
    Molecular Weight 391.5 g/mol
    Molecular Formula C26H33NO2
    XLogP35.2
    Hydrogen Bond Donor Count0
    Hydrogen Bond Acceptor Count3
    Rotatable Bond Count3
    Exact Mass391.251129295 g/mol
    Monoisotopic Mass391.251129295 g/mol
    Topological Polar Surface Area39.2 Ų
    Heavy Atom Count29
    Formal Charge0
    Complexity739
    Isotope Atom Count0
    Defined Atom Stereocenter Count6
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Zytiga is indicated with prednisone or prednisolone for:

    - the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated

    - the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

    Abiraterone Mylan is indicated with prednisone or prednisolone for:

    - the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).

    - the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.

    - the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

    Abiraterone Krka is indicated with prednisone or prednisolone for:

    - the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) (see section 5. 1)

    - the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)

    - the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Antineoplastic Agents

    Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

    Cytochrome P-450 Enzyme Inhibitors

    Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 ENZYMES. (See all compounds classified as Cytochrome P-450 Enzyme Inhibitors.)

    Steroid Synthesis Inhibitors

    Compounds that bind to and inhibit enzymes involved in the synthesis of STEROIDS. (See all compounds classified as Steroid Synthesis Inhibitors.)

    5.2 FDA Pharmacological Classification
    5.2.1 Pharmacological Classes
    Cytochrome P450 17A1 Inhibitors [MoA]; Cytochrome P450 2C8 Inhibitors [MoA]; Cytochrome P450 2D6 Inhibitors [MoA]; Cytochrome P450 17A1 Inhibitor [EPC]
    5.3 ATC Code

    L02BX03

    L02BX03

    L02BX03